Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.
Frequency Therapeutics, a US-based regenerative medicine developer based on research at Massachusetts Institute of Technology (MIT) and Harvard University, went public today in an $84m initial public offering.
The company floated at the foot of the $14 to $16 range it set last month, while reducing the number of shares in the IPO from 6.7 million to 6 million. It is valued at approximately $424m in the offering.
Frequency is developing regenerative medicines designed to use progenitor…
